Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ADK | P55263 | 1/20 | 0.40 |
| ▸ | PYGB | P11216 | 2/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 6/20 | 0.37 |
| ▸ | CA2 | P00918 | 6/20 | 0.37 |
| ▸ | GRK6 | P43250 | 2/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887049 | 0.92 | GSK3B (0.48) | GSK3BTSHRADKPYGBSLC5A2 | |
| SCHEMBL6884997 | 0.90 | GSK3B (0.37) | GSK3BTSHRADKPYGBSLC5A2 | |
| SCHEMBL9856420 | 0.88 | GSK3B (0.47) | GSK3BTSHRADKSLC5A2CA1 | |
| SCHEMBL454030 | 0.87 | GSK3B (0.48) | GSK3BTSHRADKSLC5A2CA1 | |
| SCHEMBL15019404 | 0.87 | GSK3B (0.48) | GSK3BTSHRADKSLC5A2CA1 | |
| SCHEMBL2161457 | 0.87 | GSK3B (0.48) | GSK3BTSHRADKSLC5A2CA1 | |
| SCHEMBL6887576 | 0.85 | GSK3B (0.34) | GSK3BSLC5A2CA1CA2 | |
| SCHEMBL6887317 | 0.83 | GSK3B (0.49) | GSK3BTSHRADKPYGBGAA | |
| SCHEMBL5697584 | 0.83 | GSK3B (0.49) | GSK3BTSHRADKPYGBGAA | |
| SCHEMBL5953292 | 0.83 | GSK3B (0.49) | GSK3BTSHRADKPYGBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |